Publications by authors named "Amy Axel"

Claim this Profile
P
Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma.
Christie P M Verkleij, Marloes E C Broekmans, Mark van Duin, Kristine A Frerichs, Rowan Kuiper, Amy Axel

Blood Adv· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab.
Tineke Casneuf, Homer C Adams, Niels W C J van de Donk, Yann Abraham, Jaime Bald, Amy Axel

Leukemia· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical Activity of JNJ-7957, a Novel BCMA×CD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab.
Kristine A Frerichs, Marloes E C Broekmans, Jhon A Marin Soto, Berris van Kessel, Martijn W Heymans, Amy Axel

Clin Cancer Res· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus.
Suzanne Cole, Alice Walsh, Xuefeng Yin, Mihir D Wechalekar, Malcolm D Smith, Amy Axel

Arthritis Res Ther· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma.
Tineke Casneuf, Xu Steven Xu, Homer C Adams, Amy E Axel, Christopher Chiu

Blood Adv· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to: Interference of daratumumab on the serum protein electrophoresis.
Christopher McCudden, Amy E Axel, Dominique Slaets, Thomas Dejoie, Pamela Clemens

Clin Chem Lab Med· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma.
Inger S Nijhof, Tineke Casneuf, Jeroen van Velzen, Berris van Kessel, Amy E Axel

Blood· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma.
Saad Z Usmani, Brendan M Weiss, Torben Plesner, Nizar J Bahlis, Andrew Belch, Amy Axel

Blood· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA).
Niels W C J van de Donk, Henny G Otten, Omar El Haddad, Amy Axel, A Kate Sasser

Clin Chem Lab Med· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference.
Christopher McCudden, Amy E Axel, Dominique Slaets, Thomas Dejoie, Pamela L Clemens

Clin Chem Lab Med· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interleukin-6 is a potential therapeutic target in interleukin-6 dependent, estrogen receptor-α-positive breast cancer.
Tineke Casneuf, Amy E Axel, Peter King, John D Alvarez, Jillian L Werbeck

Breast Cancer (Dove Med Press)· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Translation of a tumor microenvironment mimicking 3D tumor growth co-culture assay platform to high-content screening.
Eberhard Krausz, Ronald de Hoogt, Emmanuel Gustin, Frans Cornelissen, Thierry Grand-Perret, Amy Axel

J Biomol Screen· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic significance of interleukin-6 single nucleotide polymorphism genotypes in neuroblastoma: rs1800795 (promoter) and rs8192284 (receptor).
Joanne P Lagmay, Wendy B London, Thomas G Gross, Amanda Termuhlen, Nicholas Sullivan, Amy Axel

Clin Cancer Res· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interleukin-6 is a potent growth factor for ER-alpha-positive human breast cancer.
A Kate Sasser, Nicholas J Sullivan, Adam W Studebaker, Lindsay F Hendey, Amy E Axel

FASEB J· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human bone marrow stromal cells enhance breast cancer cell growth rates in a cell line-dependent manner when evaluated in 3D tumor environments.
A Kate Sasser, Bethany L Mundy, Kristen M Smith, Adam W Studebaker, Amy E Axel

Cancer Lett· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis